NCT01079793 is a Phase 1, PHASE2 clinical trial of ixabepilone in Prostate Cancer, sponsored by University of Texas Southwestern Medical Center.

Who is sponsoring NCT01079793?

NCT01079793 is sponsored by University of Texas Southwestern Medical Center.

What drugs are being tested in NCT01079793?

Interventions in NCT01079793: ixabepilone, adjuvant therapy, intensity-modulated radiation therapy.

What condition does NCT01079793 study?

NCT01079793 studies Prostate Cancer.

Is NCT01079793 still recruiting?

NCT01079793 is currently withdrawn. Last updated 20 August 2020.

Last reviewed 2020-08-20 · How we verify

NCT01079793

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery

Withdrawn Phase 1, PHASE2 Last updated 20 August 2020

What this trial tests

Phase 1, PHASE2 trial testing ixabepilone in Prostate Cancer. Withdrawn.

Timeline

26 May 2010

Primary endpoint
17 October 2011

17 October 2011

Quick facts

Lead sponsor	University of Texas Southwestern Medical Center
Phase	Phase 1, PHASE2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	26 May 2010
Primary completion	17 October 2011
Estimated completion	17 October 2011
Sites	1 location across United States

Drugs / interventions tested

ixabepilone (IXABEPILONE) — full drug profile →
adjuvant therapy — full drug profile →
intensity-modulated radiation therapy

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

University of Texas Southwestern Medical Center

Who can join

Adults 18 to 120, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Ixabepilone may also make tumor cells more sensitive to radiation therapy. Giving radiation therapy with chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase I/II trial is studying the side effects and best dose of ixabepilone when given together with radiation therapy to see how well it works in treating patients with high-risk stage III prostate cancer after surgery.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer.
Dal Pra A, Locke JA, Borst G, Supiot S, et al · · 2016 · cited 18× · PMID 26909338 · DOI 10.3389/fonc.2016.00024
Drug Intensification in Future Postoperative Radiotherapy Practice in Biochemically-Relapsing Prostate Cancer Patients.
Cailleteau A, Sargos P, Saad F, Latorzeff I, et al · · 2021 · cited 4× · PMID 35004302 · DOI 10.3389/fonc.2021.780507

Verify or expand the search:

Other trials of ixabepilone

Trials testing the same drug.

NCT01084057 — Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer · Phase 1 · completed

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01079793 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
Last refreshed: 20 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01079793.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing